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This commentary focuses on challenges to the widespread adoption of 
pharmacogenomics, outlining issues that need to be addressed ranging from basic 
pharmacogenomics research through to implementation. Goals addressing each challenge are 
also presented, which aim to increase understanding, assessment, interpretation, accessibility, 







Despite the established role of pharmacogenomic variation in drug efficacy and safety, 
prompting the creation of treatment guidelines by the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG), the application of 
this information into routine clinical care remains limited. In this commentary, we identify and 
attempt to address 10 challenges (Figure 1 and detailed in Table 1) that impede the widespread 
availability of genomics-guided precision medicine. 
 
Challenge 1: There is no global network of experts to help drive basic pharmacogenomics 
research and clinical implementation.  
The creation of a unified network comprised of researchers, clinicians, patients, and 
professionals from academia, government, and industry would increase the visibility and 
relevance of pharmacogenomics within the genomics and implementation science communities. 
The network could create data quality and implementation standards, which would improve 
adoption. Network members would have access to existing and new consortia, datasets, and 
could attend regular meetings. To fund network activities, including the ongoing curation of 
pharmacogenomic information, sponsorship or partnership with industry, national guideline 
organizations, regulatory bodies, and/or scientific societies that foster global initiatives while 
ensuring arms-length involvement could be considered. While there are several existing 
networks that focus on pharmacogenomics, each has its own mission, meetings, and 
membership, usually centered within a single country (e.g. Pharmacogenomics Research 
Network (PGRN), UK Pharmacogenomics and Stratified Medicine Network, and Global 




Challenge 2: Mechanistic understanding of pharmacogenomic phenotypes is hindered by 
the lack of large datasets and available bio-samples.  
Compared to datasets for complex human diseases, pharmacogenomic datasets are less 
widely available due to infrequent DNA sample collection and the need for more detailed 
phenotypic information than in complex disease. Notably, to assess drug response, it is essential 
to have phenotypic information off drug (i.e. at baseline) as well as on drug. Large, publicly 
available datasets of carefully collected DNA, RNA (including miRNA), endogenous 
metabolites, and data on drug adherence, dose, concomitant medications, and clinical outcomes 
would enhance both pharmacogenomics and comprehensive multi-omics research. Access to bio-
samples could be facilitated through the creation of a pharmacogenomics sample bank. Large 
epidemiologic and population-based studies and the collection of real-world patient data should 
be used to supplement findings from clinical studies with controlled drug administration and 
carefully selected phenotypes.  
 
Challenge 3: Compared to common genetic variation, less is known regarding the impact 
and clinical actionability of rare genetic variation.  
To identify rare variants relevant to drug response and/or adverse outcomes, very large 
sample sizes from general populations will be required. Sequence data from UK Biobank and 
other large national programs are examples of such datasets that are becoming increasingly 
available. Another approach is to study genetic founder populations and those with high rates of 
consanguinity to facilitate the identification of important rare pharmacogenomic variation. For 
instance, a GWAS of clopidogrel response in ~400 Amish individuals replicated the CYP2C19 
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locus and further identified nominal associations at other loci which can be validated through 
follow-up investigations in additional populations (2). In silico studies, including the use of 
machine learning, together with in vitro characterization and in vivo animal models, could be 
used alongside clinical studies to improve the functional prediction of rare variants, beginning 
with important pharmacogenes.  
 
Challenge 4: Models are underutilized to understand pharmacogenomic variation.  
Once significant genes are identified in GWAS, a major challenge is to understand their 
functional role(s) in drug response.  A variety of approaches, including knock-out, transgenic, 
and humanized rodent models can be leveraged to understand functional effects of variants, 
including their organ- and cell-specific impacts. Humanized rodent models are particularly useful 
when inter-species variation in ligand specificity for enzymes, transporters or other gene 
products exists. In oncology, patient-derived tumor xenograft models could help elucidate the 
impact of pharmacogenomic variation in various cancer types. 
 
Challenge 5: Validated biomarkers are an untapped resource to improve 
pharmacogenomic discovery and implementation.  
Biomarker studies including GWAS of active drug and/or metabolite levels can lead to 
the identification of novel variation associated with treatment response (3). Moreover, GWAS of 
endogenous metabolite levels can facilitate our understanding of the endogenous role of enzymes 
and transporters and identify specific metabolic biomarkers for predicting drug-drug interactions, 
as has been shown for the solute carrier transporters (4). Validated metabolic biomarkers, which 
capture environmental along with genetic influences, can be used as a surrogate for genomics in 
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situations where genetic testing is unfavorable due to disease status, clinical setting, and/or 
requirement for therapeutic drug monitoring. An expert working group (see Challenge 1) could 
develop criteria to determine which biomarkers are specific for which genes and determine the 
relative contribution of genetics and environment to functional variation. The consideration of 
environmental influences and additional patient factors will enable the development of more 
comprehensive tailoring algorithms.  
 
Challenge 6: Special and diverse populations are understudied.  
 To increase the power for genetic discovery, enhance clinical relevance, and ensure the 
democratization and accessibility of pharmacogenomics, studies in ethnically diverse world 
populations are essential. To meet the goal of implementing tailored treatment algorithms, a 
comprehensive understanding of genomic variation is required; initiatives such as the African 
Genome Variation Project (https://www.sanger.ac.uk/science/collaboration/african-genome-
variation-project) aim to reduce the existing information gap. Local pharmacogenomic research 
capacity should be fostered in developing countries using the support of Western training 
initiatives. Special populations such as children, the elderly, and pregnant women should also be 
considered, to elucidate the contribution of genetic variation and non-genetic factors (e.g. 
development, comorbid illness) to interindividual variability of expression and function of 
pharmacogenes. 
 




Collaboration with the medical technology industry and organizations that create 
minimum acceptable standards would expedite the creation of reliable and affordable 
pharmacogenomic tests with universally accepted criteria. Test providers will need to consider 
the complexity of pharmacogene variant calling (due to homologous pseudogenes and structural 
variation) to optimize the use of whole gene sequencing versus precise calling of actionable 
variants. Because poor quality bio-samples can produce spurious results, laboratory standards for 
the source and quality of DNA will also need to be created. Groups such as AMP and CAP are 
working to set minimum standards and proficiency testing. 
 To improve the use of pharmacogenetic results, testing will need to be performed pre-
emptively, at point-of-care or in routine labs with rapid turnaround time of standardized results.  
Healthcare practitioners will need to be further educated and clinical decision support systems 
will help in optimizing decision making. The incorporation of point-of-care genotype testing was 
shown to improve anticoagulation control in patients treated with warfarin (5); while received 
favorably by >90% of patients, staff felt that the turnaround time of 45 minutes increased the 
length of the clinic (5). The most efficient procedure would involve linking one-time genetic test 
results to longitudinally available electronic health records (EHRs), prescribing systems, and 
laboratory records; this would require a sophisticated informatics infrastructure that ensures 
patient data protection. 
 
Challenge 8: Successful widespread pharmacogenomic implementation is limited.  
In addition to addressing Challenges 1-7, multidisciplinary teams of medical leads, 
scientists, laboratory technicians, and pharmacists should be encouraged to become early 
adopters of pharmacogenomics. We need to create a learning healthcare system through 
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prospective empirically-based implementation trials, where data from historical controls can be 
used when withholding testing is unethical; for example, prospective DPYD genotype-guided 
therapy was shown to reduce the risk of fluoropyrimidine-associated toxicity (6). The effect of 
implementation on a system-wide level is currently unknown; Genomics England’s 100,000 
Genomes Project will pilot and iteratively evaluate the impact of implementing prioritized gene-
drug pairs on the whole of England’s National Health Service (NHS) (7).  
There is substantial interest in testing cost-effectiveness of implementation. England’s 
NHS is currently determining which gene-drug pairs should be prioritized for country-wide 
implementation. The criteria will include allele frequency, evidence of clinical benefit, frequency 
of drug use, polypharmacy, cost-effectiveness, and technical considerations (7). The usability of 
EHRs must also be greatly improved, including the use of standardized phenotypes and 
harmonized data reports along with relevant follow-up data, and support must be provided to 
health care providers to reduce the time burden of data entry. The creation of an alert-based 
system searchable by drug or gene name, along with appropriate clinical decision support, is also 
required. 
 
Challenge 9: Education and advocacy initiatives are needed to increase the adoption of 
pharmacogenomics. 
 Tailored educational innovations for various stakeholders (e.g. patients, clinicians, 
ministries of health, insurance companies) are required to increase adoption. A training program 
implementing personalized genetic testing has already been shown to be an effective pedagogical 
tool among medical students at the University of Maryland School of Medicine (8). Educational 
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strategies that highlight the high prevalence of actionable pharmacogenomic variation in the 
context of current prescribing patterns (9) are important.  
 
Challenge 10: Additional Challenge: The threshold for clinical actionability based on cell-
free DNA testing is unknown. 
In oncology, cell-free DNA testing complements germline DNA testing and may be 
particularly useful for monitoring treatment resistance (10). For clinical implementation, a 
consensus must be reached regarding the threshold of mutational burden in cell-free DNA reads 
to consider actionability. In immune therapy, assessment of tumor neoantigen load in addition to 
mutational burden will be required. Methods that differentiate normal mosaicism from tumor 
DNA are needed to ensure the validity of cell-free DNA testing, as are those that detect and 
predict the functionality of minor clones.  
 
Conclusion 
Despite established associations between pharmacogenomic variation and treatment 
response, the clinical implementation of this information lags. Improving basic 
pharmacogenomics research, including rare variant analyses and studies in diverse populations, 
together with initiatives focused on embedding pharmacogenomics within health care systems 
(e.g. 100,000 Genomes Project (7)), will provide invaluable insights that will help pave the way 





These topics were examined during the ninth Dr. Antoni Esteve Foundation Discussion 
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Figure 1. 10 identified challenges that currently limit the widespread clinical 
implementation of pharmacogenomics. These challenges range from not having a global 
unified network to help drive pharmacogenomics initiatives, to gaps within discovery research 
and our poor understanding of genomics within special and diverse populations. There is also a 
lack of available standardized tests and reports, poor integration of pharmacogenomic 
information within existing electronic health and laboratory records, a need to incentivize early 
adoption of pharmacogenomics and outcome studies in the context of a learning health care 




Challenge Goals for Improvement 
#1: There is no global network of 
experts to help drive basic 
pharmacogenomics research and 
clinical implementation 
 Create a global pharmacogenomics network comprising researchers, 
clinicians, patient representatives, and other professionals from 
academia, government, and industry 
 The goal of the network is to advance pharmacogenomics research and 
implementation in both developed and resource limited countries 
 Provide network members access to existing and new consortia, 
datasets, and regular meetings 
 Create a list of standards for data quality and implementation to improve 
the adoption of clinical pharmacogenomic testing 
 Consider sponsorship by or partnership with industry, national guideline 
organizations, regulatory bodies, and/or scientific societies to provide 
the infrastructure needed for network activities while ensuring arms-
length involvement 
 Increase the visibility of pharmacogenomics within human genomics 
circles 
#2: Mechanistic understanding of 
pharmacogenomic phenotypes is 
hindered by the lack of large 
datasets and available bio-samples 
 Increase the availability of publicly available datasets that include drug 
adherence, doses, and concomitant medications along with before drug 
and on-drug phenotypic information from patients from multiple ethnic 
groups, and particularly non-Europeans 
 Accumulate large samples of individuals with DNA, RNA (including 
miRNA), endogenous metabolites, and kinetic assessments to allow for 
comprehensive -omics research 
 Assemble a pharmacogenomics sample bank, which includes 
appropriately banked samples such as blood and urine from individuals 
from multiple ethnic groups on drugs, and control individuals 
 Consider collection of real-world data from patients to supplement 
pharmacogenomics research 
#3: Compared to common genetic 
variation, less is known regarding 
the impact and clinical actionability 
of rare genetic variation 
 Conduct studies in founder populations and populations with high rates 
of consanguinity that are enriched for homozygous rare variation 
 Acquire sufficiently large samples (e.g. blood, urine, tissues) and 
optimize methods to examine the functional and clinical impact of rare 
and common variation together 
 Use multi-omics approaches to better assess in vivo functional 
consequences 
 Use machine learning approaches to improve functional prediction for 
rare variants, beginning with important pharmacogenes  
 Use innovative experimental approaches to examine mechanistic 
consequences of rare variants in vitro 
#4: Models are underutilized to 
understand pharmacogenomic 
variation 
 Use knock-out, knock-in, and humanized rodent models to understand 
functional variation, including identifying the physiologic and 
pharmacological roles of transporters and enzymes  
 Consider humanized mouse models as a tool to improve 
pharmacological studies, especially when ligand specificity of the 
encoded protein differs by species 
 Investigate organ and cell-specific impacts of genetic variants using 
animal models 
 Use patient-derived tumor xenograft models to elucidate 
pharmacogenomic variation in various cancer types 
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#5: Validated biomarkers are an 
untapped resource to improve 
pharmacogenomic discovery and 
implementation 
 Recruit drug-naïve populations to study and validate specific metabolic 
biomarkers as surrogates for genotypes, especially in instances where 
genetic testing is not available  
 Perform genome-wide association studies of drug and metabolite levels 
to identify predictors of treatment response 
 Study endogenous metabolites to improve understanding of enzyme and 
transporter function 
 Create a set of criteria to determine which biomarkers are specific and 
valid for which genes  
 Determine the relative utility of pharmacogenomic testing versus 
biomarker assessments, while taking into consideration the disease, 
clinical setting, treatment selection, dosing, and medication adherence 
 Through measured biomarkers, determine the relative contribution of 
genetics and environment to functional variation 
#6: Special and diverse populations 
are understudied 
 Investigate genomic variation in multiple world populations to increase 
the power for genetic discovery, increase clinical relevance, and ensure 
democratization and accessibility of pharmacogenomics  
 Develop tailored pharmacogenomic algorithms that consider population 
differences in allele frequencies and functional variation  
 Support local pharmacogenomic research capacity in developing 
countries through Western training initiatives  
 Ensure diverse and special populations derive benefit from conducted 
research and avoid invoking further inequalities 
 Harness machine learning to improve functional variant prediction to 
reduce reliance on clinical studies 
 Consider special populations (e.g. children, elderly) to elucidate the 
contribution of genetic variation and non-genetic factors (e.g. 
development, comorbid illness) to interindividual variability of expression 
and function of pharmacogenes 
#7: Many pharmacogenomic tests 
are not standardized, which limits 
utility of test results 
 Collaborate closely with the medical technology industry to drive the 
creation of reliable and affordable pharmacogenomic tests, with 
universally accepted standards  
 Educate test manufacturers regarding the complexity of pharmacogene 
variant calling due to the presence of pseudogenes, copy number 
variation, and structural variation 
 For pharmacogenes, optimize the use of whole gene sequence versus 
precise calling in regions containing actionable variants 
 Identify scenarios where strand-specific haplotyping would be useful 
 Create laboratory standards for the source and quality of DNA 
 Administer pharmacogenomic tests pre-emptively or with rapid 
turnaround time to promote utility in hospital-based medicine  
 Create a set of clinical decision support guidelines and train health care 
practitioners to both administer and interpret test results 
 Develop infrastructure to link one-time genetic test results to 
longitudinally available electronic health records and ensure data 
protection 
 
#8: Successful widespread 
pharmacogenomic implementation 
is limited 
 Create multidisciplinary teams of medical leads, scientists, laboratory 
technicians, and pharmacists 
 Promote learning health systems through prospective empirically-based 
implementation trials 
 Encourage health systems to become early adopters of 
pharmacogenomics 
 Develop health economic models to show cost-effectiveness of 
implementation 
 Improve the usability of electronic health records 
o Introduce standardized phenotypes and harmonized data reporting 
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o Include relevant follow-up data 
o Consider creation and adoption of alert-based system searchable by 
drug or gene name which may be improved by machine learning 
approaches 
o Update clinical decision support as more information becomes 
available regarding functional consequences of variants 
o Provide support, e.g. via a clinical research coordinator, to health 
care providers to reduce the time burden of entering information 
 
#9: Education and advocacy 
initiatives are needed to increase 
the adoption of pharmacogenomics 
 Develop educational materials, fact sheets, and training programs 
concerning the health and economic benefits of implementing genomics-
guided medicine  
 Educate all relevant stakeholders (e.g. patients, providers, ministries of 
health, healthcare insurance companies, etc.) regarding the benefits of 
pharmacogenomic implementation, using N-of-1 to Phase IV studies and 
post-utilization evidence 
 Educate stakeholders regarding the difficulty of proving that a 
pharmacogenomic intervention has improved care: treatment has 
generally improved over time (historic controls may not be appropriate), 
withholding pharmacogenomic testing from a control group is not ethical, 
and it is impossible to track the prevention of poor outcomes 
Highlight the unmet need by emphasizing the high prevalence of 
actionable pharmacogenomic variation in the context of current 
prescribing and drug use patterns 
#10: Additional Challenge:  
The threshold for clinical 
actionability based on cell-free DNA 
testing is unknown 
 Investigate the promise of cell-free DNA testing, including regarding 
epigenetic mechanisms (i.e. DNA methylation), as a complement to 
germline DNA testing 
 Determine the threshold of mutational burden in cell-free DNA reads to 
consider clinical actionability  
 Consider tumor antigen load together with mutation load to optimize 
immune therapy in cancer treatment  
 Determine how to differentiate normal mosaicism from tumor DNA 
 Optimize the detection and functional prediction of minor clones 
 
 
 
 
 
 
